Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

Linking prostate cancer cell AR heterogeneity to distinct castration and enzalutamide responses.

Li Q, Deng Q, Chao HP, Liu X, Lu Y, Lin K, Liu B, Tang GW, Zhang D, Tracz A, Jeter C, Rycaj K, Calhoun-Davis T, Huang J, Rubin MA, Beltran H, Shen J, Chatta G, Puzanov I, Mohler JL, Wang J, Zhao R, Kirk J, Chen X, Tang DG.

Nat Commun. 2018 Sep 6;9(1):3600. doi: 10.1038/s41467-018-06067-7.

2.

Cancer stem cells: Regulation programs, immunological properties and immunotherapy.

Zhang D, Tang DG, Rycaj K.

Semin Cancer Biol. 2018 Oct;52(Pt 2):94-106. doi: 10.1016/j.semcancer.2018.05.001. Epub 2018 May 9. Review.

PMID:
29752993
3.

Molecular determinants of prostate cancer metastasis.

Rycaj K, Tang DG.

Oncotarget. 2017 Sep 19;8(50):88211-88231. doi: 10.18632/oncotarget.21085. eCollection 2017 Oct 20. Review.

4.

Cellular determinants and microenvironmental regulation of prostate cancer metastasis.

Rycaj K, Li H, Zhou J, Chen X, Tang DG.

Semin Cancer Biol. 2017 Jun;44:83-97. doi: 10.1016/j.semcancer.2017.03.009. Epub 2017 Apr 11. Review.

5.

Developing a Novel Two-Dimensional Culture System to Enrich Human Prostate Luminal Progenitors that Can Function as a Cell of Origin for Prostate Cancer.

Zhang D, Lin K, Lu Y, Rycaj K, Zhong Y, Chao HP, Calhoun-Davis T, Shen J, Tang DG.

Stem Cells Transl Med. 2017 Mar;6(3):748-760. doi: 10.5966/sctm.2016-0243. Epub 2016 Sep 29.

6.

MicroRNA-141 suppresses prostate cancer stem cells and metastasis by targeting a cohort of pro-metastasis genes.

Liu C, Liu R, Zhang D, Deng Q, Liu B, Chao HP, Rycaj K, Takata Y, Lin K, Lu Y, Zhong Y, Krolewski J, Shen J, Tang DG.

Nat Commun. 2017 Jan 23;8:14270. doi: 10.1038/ncomms14270.

7.

NANOG reprograms prostate cancer cells to castration resistance via dynamically repressing and engaging the AR/FOXA1 signaling axis.

Jeter CR, Liu B, Lu Y, Chao HP, Zhang D, Liu X, Chen X, Li Q, Rycaj K, Calhoun-Davis T, Yan L, Hu Q, Wang J, Shen J, Liu S, Tang DG.

Cell Discov. 2016 Nov 15;2:16041. eCollection 2016.

8.

miR-199a-3p targets stemness-related and mitogenic signaling pathways to suppress the expansion and tumorigenic capabilities of prostate cancer stem cells.

Liu R, Liu C, Zhang D, Liu B, Chen X, Rycaj K, Jeter C, Calhoun-Davis T, Li Y, Yang T, Wang J, Tang DG.

Oncotarget. 2016 Aug 30;7(35):56628-56642. doi: 10.18632/oncotarget.10652.

9.

Defining a Population of Stem-like Human Prostate Cancer Cells That Can Generate and Propagate Castration-Resistant Prostate Cancer.

Chen X, Li Q, Liu X, Liu C, Liu R, Rycaj K, Zhang D, Liu B, Jeter C, Calhoun-Davis T, Lin K, Lu Y, Chao HP, Shen J, Tang DG.

Clin Cancer Res. 2016 Sep 1;22(17):4505-16. doi: 10.1158/1078-0432.CCR-15-2956. Epub 2016 Apr 8.

10.

Stem cell and neurogenic gene-expression profiles link prostate basal cells to aggressive prostate cancer.

Zhang D, Park D, Zhong Y, Lu Y, Rycaj K, Gong S, Chen X, Liu X, Chao HP, Whitney P, Calhoun-Davis T, Takata Y, Shen J, Iyer VR, Tang DG.

Nat Commun. 2016 Feb 29;7:10798. doi: 10.1038/ncomms10798.

11.

Longitudinal tracking of subpopulation dynamics and molecular changes during LNCaP cell castration and identification of inhibitors that could target the PSA-/lo castration-resistant cells.

Rycaj K, Cho EJ, Liu X, Chao HP, Liu B, Li Q, Devkota AK, Zhang D, Chen X, Moore J, Dalby KN, Tang DG.

Oncotarget. 2016 Mar 22;7(12):14220-40. doi: 10.18632/oncotarget.7303.

12.

Cell-of-Origin of Cancer versus Cancer Stem Cells: Assays and Interpretations.

Rycaj K, Tang DG.

Cancer Res. 2015 Oct 1;75(19):4003-11. doi: 10.1158/0008-5472.CAN-15-0798. Epub 2015 Aug 19. Review.

13.

Systematic dissection of phenotypic, functional, and tumorigenic heterogeneity of human prostate cancer cells.

Liu X, Chen X, Rycaj K, Chao HP, Deng Q, Jeter C, Liu C, Honorio S, Li H, Davis T, Suraneni M, Laffin B, Qin J, Li Q, Yang T, Whitney P, Shen J, Huang J, Tang DG.

Oncotarget. 2015 Sep 15;6(27):23959-86.

14.

Cancer stem cells and cell size: A causal link?

Li Q, Rycaj K, Chen X, Tang DG.

Semin Cancer Biol. 2015 Dec;35:191-9. doi: 10.1016/j.semcancer.2015.07.002. Epub 2015 Aug 1. Review.

15.

Targeted therapy against cancer stem cells.

Yang T, Rycaj K.

Oncol Lett. 2015 Jul;10(1):27-33. Epub 2015 May 4.

16.

Cytotoxicity of human endogenous retrovirus K-specific T cells toward autologous ovarian cancer cells.

Rycaj K, Plummer JB, Yin B, Li M, Garza J, Radvanyi L, Ramondetta LM, Lin K, Johanning GL, Tang DG, Wang-Johanning F.

Clin Cancer Res. 2015 Jan 15;21(2):471-83. doi: 10.1158/1078-0432.CCR-14-0388. Epub 2014 Nov 4.

17.

Cancer stem cells: constantly evolving and functionally heterogeneous therapeutic targets.

Yang T, Rycaj K, Liu ZM, Tang DG.

Cancer Res. 2014 Jun 1;74(11):2922-7. doi: 10.1158/0008-5472.CAN-14-0266. Epub 2014 Apr 8.

18.

Nanog1 in NTERA-2 and recombinant NanogP8 from somatic cancer cells adopt multiple protein conformations and migrate at multiple M.W species.

Liu B, Badeaux MD, Choy G, Chandra D, Shen I, Jeter CR, Rycaj K, Lee CF, Person MD, Liu C, Chen Y, Shen J, Jung SY, Qin J, Tang DG.

PLoS One. 2014 Mar 5;9(3):e90615. doi: 10.1371/journal.pone.0090615. eCollection 2014.

19.

Cancer stem cells and radioresistance.

Rycaj K, Tang DG.

Int J Radiat Biol. 2014 Aug;90(8):615-21. doi: 10.3109/09553002.2014.892227. Epub 2014 Mar 7. Review.

20.

Human endogenous retrovirus type K antibodies and mRNA as serum biomarkers of early-stage breast cancer.

Wang-Johanning F, Li M, Esteva FJ, Hess KR, Yin B, Rycaj K, Plummer JB, Garza JG, Ambs S, Johanning GL.

Int J Cancer. 2014 Feb 1;134(3):587-95. doi: 10.1002/ijc.28389. Epub 2013 Sep 13.

21.

New insights into prostate cancer stem cells.

Chen X, Rycaj K, Liu X, Tang DG.

Cell Cycle. 2013 Feb 15;12(4):579-86. doi: 10.4161/cc.23721. Epub 2013 Jan 31. Review.

22.

Expression of Human Endogenous Retrovirus Type K Envelope Protein is a Novel Candidate Prognostic Marker for Human Breast Cancer.

Zhao J, Rycaj K, Geng S, Li M, Plummer JB, Yin B, Liu H, Xu X, Zhang Y, Yan Y, Glynn SA, Dorsey TH, Ambs S, Johanning GL, Gu L, Wang-Johanning F.

Genes Cancer. 2011 Sep;2(9):914-22. doi: 10.1177/1947601911431841.

23.

Immunotherapeutic potential of anti-human endogenous retrovirus-K envelope protein antibodies in targeting breast tumors.

Wang-Johanning F, Rycaj K, Plummer JB, Li M, Yin B, Frerich K, Garza JG, Shen J, Lin K, Yan P, Glynn SA, Dorsey TH, Hunt KK, Ambs S, Johanning GL.

J Natl Cancer Inst. 2012 Feb 8;104(3):189-210. doi: 10.1093/jnci/djr540. Epub 2012 Jan 12.

24.

Human endogenous retrovirus K triggers an antigen-specific immune response in breast cancer patients.

Wang-Johanning F, Radvanyi L, Rycaj K, Plummer JB, Yan P, Sastry KJ, Piyathilake CJ, Hunt KK, Johanning GL.

Cancer Res. 2008 Jul 15;68(14):5869-77. doi: 10.1158/0008-5472.CAN-07-6838.

25.

Sheep stromal-epithelial cell interactions and ovarian tumor progression.

Wang-Johanning F, Huang M, Liu J, Rycaj K, Plummer JB, Barnhart KF, Satterfield WC, Johanning GL.

Int J Cancer. 2007 Nov 15;121(10):2346-54.

26.

Expression of multiple human endogenous retrovirus surface envelope proteins in ovarian cancer.

Wang-Johanning F, Liu J, Rycaj K, Huang M, Tsai K, Rosen DG, Chen DT, Lu DW, Barnhart KF, Johanning GL.

Int J Cancer. 2007 Jan 1;120(1):81-90.

Supplemental Content

Support Center